Satoshi Matsusaka

Dr. Satoshi Matsusaka


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MKMasahiro kozuka
Masahiro kozuka
FBFrancesca Battaglin
Francesca Battaglin
PJPriya Jayachandran
Priya Jayachandran
JWJingyuan Wang
Jingyuan Wang
HAHIROYUKI ARAI
HIROYUKI ARAI
HLHeinz-Josef Lenz
Heinz-Josef Lenz
Background: Circulating tumor cells (CTCs) are a prognostic marker in patients with metastatic colorectal cancer (mCRC). However, little is known about the characterization of CTCs in mCRC at the single-cell level using RNA sequencing. The purpose of this study was to validate the capability to detect and isolate single CTCs for single-cell RNA sequencing (scRNA-seq) and to identify clinical significance at a single CTC level. Methods: Single CTCs from 27 mCRC patients were collected by CTC-FIND, which is comprised of filter separation and immunomagnetic depletion to collect ultra-pure CTC samples. To address tumor heterogeneity, CTCs were collected without relying on any traditional CTC markers, such as epithelial and mesenchymal cell antigens, and were undertaken by scRNA-seq using SMART-Seq v4. Results: We identified 59 single CTCs which were classified into four groups by epithelial, epithelial-mesenchymal transition (EMT) and stem cell-related gene expression. Patients receiving second or later-line treatment who had EMT gene expressing CTCs had a significantly shorter PFS and OS. Conclusions: Exploiting CTC-FIND with SMART-Seq v4 showed that scRNA-seq of CTCs may shed new insight into tumor heterogeneity of mCRC and that the presence of CTCs expressing EMT-related genes at the single-cell level could have prognostic value in mCRC patients.

10 January 2023 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
HMHiroki Matsumura
Hiroki Matsumura
LSLarina TzuWei Shen
Larina TzuWei Shen
AIAkihiro Isozaki
Akihiro Isozaki
HMHideharu Mikami
Hideharu Mikami
DYDan Yuan
Dan Yuan
SMSatoshi Matsusaka
Satoshi Matsusaka
Heterogeneous clusters of cancer cells and leukocytes in blood were visualized by combining high-throughput and high-sensitivity fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation.

13 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NVNico B. Volz
Nico B. Volz
DHDiana Hanna
Diana Hanna
Sebastian StintzingSebastian Stintzing
Sebastian Stintzing
WZWu Zhang
Wu Zhang
DYDongyun Yang
Dongyun Yang
HLHeinz-Josef Lenz
Heinz-Josef Lenz
Cetuximab, an IgG1 EGFR-directed antibody, promotes antibody-dependent cell-mediated cytotoxicity. We hypothesized that single-nucleotide polymorphisms (SNPs) in immune regulatory pathways may predict outcomes in patients with metastatic colorectal cancer treated with cetuximab-based regimens. A total of 924 patients were included: 105 received cetuximab in IMCL-0144 and cetuximab/irinotecan in GONO-ASL608LIOM01 (training cohort), 225 FOLFIRI/cetuximab in FIRE-3 (validation cohort 1), 74 oxaliplatin/cetuximab regimens in JACCRO CC-05/06 (validation cohort 2), and 520 FOLFIRI/bevacizumab in FIRE-3 and TRIBE (control cohorts). Twelve SNPs in five genes (IDO1; PD-L1; PD-1; CTLA-4; CD24) were evaluated by PCR-based direct sequencing. We analyzed associations between genotype and clinical outcomes. In the training cohort; patients with the CD24 rs52812045 A/A genotype had a significantly shorter median PFS and OS than those with the G/G genotype (PFS 1.3 vs. 3.6 months; OS 2.3 vs. 7.8 months) in univariate (PFS HR 3.62; p = 0.001; OS HR 3.27; p = 0.0004) and multivariate (PFS HR 3.18; p = 0.009; OS HR 4.93; p = 0.001) analyses. Similarly; any A allele carriers in the JACCRO validation cohort had a significantly shorter PFS than G/G carriers (9.2 vs. 11.8 months; univariate HR 1.90; p = 0.011; multivariate HR 2.12; p = 0.018). These associations were not demonstrated in the control cohorts. CD24 genetic variants may help select patients with metastatic colorectal cancer most likely to benefit from cetuximab-based therapy.

5 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
KOKauzmasa Oya
Kauzmasa Oya
LSLarina TzuWei Shen
Larina TzuWei Shen
KMKazushi Maruo
Kazushi Maruo
SMSatoshi Matsusaka
Satoshi Matsusaka
The antitumor effect of antibody-drug conjugates (ADC) is the main factor in achieving cures. Although the mechanism of tumor resistance to treatment is multifaceted, tumor-derived extracellular vesicles (T-EVs) have been implicated as contributing to the attenuation of ADC therapeutic efficacy. Thus, strategies to eliminate T-EVs are highly promising for overcoming drug resistance. Here we demonstrate plasma exchange therapy to remove T-EVs, decreasing their amount in vitro by 75%. Although trastuzumab emtansine (T-DM1) treatment alone was effective in our rat tumor model, the combination therapy of T-DM1 and T-EV filtration achieved early tumor shrinkage. Our results indicate that T-EV filtration plus ADC is a promising strategy for overcoming drug resistance.

28 September 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
TSTomoaki Sonoda
Tomoaki Sonoda
NYNoriko Yanagitani
Noriko Yanagitani
KSKanako Suga
Kanako Suga
TYTakahiro Yoshizawa
Takahiro Yoshizawa
SNShingo Nishikawa
Shingo Nishikawa
SMSatoshi Matsusaka
Satoshi Matsusaka
Background/Aim: Clusters of circulating tumor cells (CTCs) increase metastatic potential compared to single CTC. However, conventional technologies have been unable to generate an accurate analysis of single and cluster CTCs in the peripheral blood. We propose an effective strategy to detect and isolate both single and cluster CTCs using two size-selective microfilters. Materials and Methods: Five ml of whole blood were collected from 10 patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. Single and cluster CTCs were identified using precision microfiltration membranes with two distinct pore sizes together with anti-EpCAM antibody labeling. Results: Single and cluster CTCs were detected by simultaneously using two size-selective microfilters. The EGFR-L858R mutation was detected in the DNA from cells captured using both microfilters. Conclusion: Our method can be used to detect and isolate single and cluster CTCs in the whole blood and may facilitate the development of a liquid biopsy strategy.

31 March 2023 in Oncology Reports
Verified
Journal Article
Open access
PDF file
AFAtsuko Furukawa
Atsuko Furukawa
TMTomoko Mori
Tomoko Mori
OSOsamu Shimomura
Osamu Shimomura
KAKazuhisa Araki
Kazuhisa Araki
TOTatsuya Oda
Tatsuya Oda
SMSatoshi Matsusaka
Satoshi Matsusaka
Circulating tumor cells (CTCs) are associated with cancer metastasis and prognosis but their scarcity in whole blood prevents their use as a diagnostic tool. The purpose of the present study was to establish a novel approach to capture and cultivate CTCs using a microfilter device. The present study was a prospective study of patients with pancreatic cancer at the University of Tsukuba Hospital (Tsukuba, Japan). From each patient, 5 ml of whole blood was collected into an EDTA collection tube. Whole blood was filtered to isolate CTCs and cells captured on the microfilter were cultured in place. A total of 15 patients were enrolled. CTCs and/or CTC clusters were detected in 2 of 6 cases on day 0. In all cases, CTCs and/or formed clusters and/or colonies were observed during long‑term culture periods of up to 103 days. In samples where CTCs were not immediately evident, CTC clusters and colonies emerged after long‑term culture. To confirm activity of the cultured CTCs on the filters, staining with Calcein AM was performed and epithelial cellular adhesion molecule‑positive cells were observed. The system enables the capture and culture of CTCs. Cultured CTCs may be used for patient‑specific drug susceptibility testing and genomic profiling of cancer.